fig1
Figure 1. Proposed gut-heart axis pathways linking cancer therapies to CTRCT and candidate microbiome-guided interventions. Pathways shown are hypothesized on the basis of preclinical and mechanistic data and have not been validated against cardiovascular endpoints in humans. SCFA: Short-chain fatty acid; TMAO: trimethylamine N-oxide; PAGln: phenylacetylglutamine; CD8+: Cluster of differentiation 8; NLRP3: NOD-like receptor family pyrin domain containing 3; Treg: regulatory T cell; FMT: fecal microbiota transplantation.





